Skip to main content

Advertisement

SpringerLink
Log in

Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes

  • Original Article
  • Published:
Tumor Biology

Abstract

This study aimed to evaluate the clinical correlations between serum lactate dehydrogenase (LDH) levels and tumor characteristics and to investigate the prognostic impact of serum LDH levels in advanced non-small cell lung cancer (NSCLC). A total of 394 patients were included in the present study between June 2007 and January 2013. All eligible patients had serum LDH levels available before treatment, and whole-body metastatic extent was measured using whole-body metastatic scores, as determined by 18(F)-fludeoxyglucose positron emission tomography scans from 1 to 7 as the sum of each metastatic region. The diagnostic cutoff value for an abnormal serum LDH level was 450 IU/L. The median serum LDH level was 477 IU/L (range, 113–2850), and 224 (56.9 %) patients had abnormal serum LDH levels. The serum LDH levels showed no significant associations with age, gender, histology, tumor differentiation, and smoking history. However, the proportion of patients with abnormal serum LDH levels was statistically significantly higher in the high total metastatic score group (scores 3–7) than in the low total metastatic score group (scores 1–2) (65.3 vs 50.4 %, p = 0.001). In a multivariate survival analysis, age (p = 0.001), gender (p = 0.001), histology (p = 0.003), tumor differentiation (p = 0.001), Eastern Cooperative Oncology Group (ECOG) performance status (p = 0.001), LDH levels (p = 0.046), and treatment factors (p = 0.001) proved to be independent prognostic factors for survival outcomes. The results of this study suggest that the serum LDH levels at presentation may be significantly correlated with whole-body tumor extent and might independently but modestly prognosticate OS in stage IV NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  2. O'Connell JP, Kris MG, Gralla RJ, Groshen S, Trust A, Fiore JJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol. 1986;4:1604–14.

    Article  PubMed  Google Scholar 

  3. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991;9:1618–26.

    Article  CAS  PubMed  Google Scholar 

  4. Espinosa E, Feliu J, Zamora P, Gonzalez Baron M, Sanchez JJ, Ordon EZA, et al. Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer. 1995;12:67–76.

    Article  CAS  PubMed  Google Scholar 

  5. Hespanhol V, Queiroga H, Magalhaes A, Santos AR, Coelho M, Marques A. Survival predictors in advanced non-small cell lung cancer. Lung Cancer. 1995;13:253–67.

    Article  CAS  PubMed  Google Scholar 

  6. Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, et al. Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer. 2001;85:1634–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Klastersky J, Paesmans M. Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results. Lung Cancer. 2001;34 Suppl 4:S95–101.

    Article  PubMed  Google Scholar 

  8. Jeremic B, Milicic B, Dagovic A, Aleksandrovic J, Nikolic N. Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy. J Cancer Res Clin Oncol. 2003;129:114–22.

    Article  CAS  PubMed  Google Scholar 

  9. Toh CK. The changing epidemiology of lung cancer. Methods Mol Biol. 2009;472:397–411.

    Article  PubMed  Google Scholar 

  10. Konopa K, Jassem J. The role of pemetrexed combined with targeted agents for non-small cell lung cancer. Curr Drug Targets. 2010;11:2–11.

    Article  CAS  PubMed  Google Scholar 

  11. Somaiah N, Simon GR. Molecular targeted agents and biologic therapies for non-small cell lung cancer. J Thorac Oncol. 2010;5:S434–54.

    Article  PubMed  Google Scholar 

  12. Tas F, Aydiner A, Demir C, Topuz E. Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer. Am J Clin Oncol. 2001;24:376–8.

    Article  CAS  PubMed  Google Scholar 

  13. Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC, et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer. 2003;89:877–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Koukourakis MI, Giatromanolaki A, Sivridis E. Tumour, Angiogenesis Research G. Lactate dehydrogenase isoenzymes 1 and 5: differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. Tumour Biol. 2003;24:199–202.

    Article  CAS  PubMed  Google Scholar 

  15. Scartozzi M, Giampieri R, Maccaroni E, Del Prete M, Faloppi L, Bianconi M, et al. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br J Cancer. 2012;106:799–804.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Faloppi L, Scartozzi M, Bianconi M, Svegliati Baroni G, Toniutto P, Giampieri R, et al. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer. 2014;14:110.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Watine J. Prognostic evaluation of primary non-small cell lung carcinoma patients using biological fluid variables. A systematic review. Scand J Clin Lab Invest. 2000;60:259–73.

    Article  CAS  PubMed  Google Scholar 

  18. Wang S, Han X, Hu X, Wang X, Zhao L, Tang L, et al. Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients. Clin Chim Acta. 2014;430:63–70.

    Article  CAS  PubMed  Google Scholar 

  19. Lee DS, Kim SJ, Kang JH, Hong SH, Jeon EK, Kim YK, et al. Serum carcinoembryonic antigen levels and the risk of whole-body metastatic potential in advanced non-small cell lung cancer. J Cancer. 2014;5:663–9.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Lee DS, Kim YS, Jung SL, Lee KY, Kang JH, Park S, et al. The relevance of serum carcinoembryonic antigen as an indicator of brain metastasis detection in advanced non-small cell lung cancer. Tumour Biol. 2012;33:1065–73.

    Article  CAS  PubMed  Google Scholar 

  21. Lee DS, Kang JH, Lee CG, Kim SJ, Choi YJ, Lee KY, et al. Predicting survival in patients with advanced non-squamous non-small cell lung cancer: validating the extent of metastasis. Cancer Res Treat. 2013;45:95–102.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer. 1987;39:146–9.

    Article  CAS  PubMed  Google Scholar 

  23. Byhardt RW, Hartz A, Libnoch JA, Hansen R, Cox JD. Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL). Int J Radiat Oncol Biol Phys. 1986;12:771–7.

    Article  CAS  PubMed  Google Scholar 

  24. Ferrigno D, Buccheri G, Camilla T. Serum copper and zinc content in non-small cell lung cancer: abnormalities and clinical correlates. Monaldi Arch Chest Dis. 1999;54:204–8.

    CAS  PubMed  Google Scholar 

  25. Ray P, Quantin X, Grenier J, Pujol JL. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. Cancer Detect Prev. 1998;22:293–304.

    Article  CAS  PubMed  Google Scholar 

  26. Goldman RD, Kaplan NO, Hall TC. Lactic dehydrogenase in human neoplastic tissues. Cancer Res. 1964;24:389–99.

    CAS  PubMed  Google Scholar 

  27. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Trarbach T, Folprecht G, et al. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin Cancer Res. 2011;17:4892–900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Yang Y, Su D, Zhao L, Zhang D, Xu J, Wan J, et al. Different effects of LDH-A inhibition by oxamate in non-small cell lung cancer cells. Oncotarget. 2014;5:11886–96.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Charloux A, Quoix E, Wolkove N, Small D, Pauli G, Kreisman H. The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol. 1997;26:14–23.

    Article  CAS  PubMed  Google Scholar 

  30. Uhm JE, Park BB, Ahn MJ, Lee J, Ahn JS, Kim SW, et al. Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group. J Thorac Oncol. 2009;4:1136–43.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, College of Medicine, The Catholic University of Korea, Seoul, South Korea

    Dong Soo Lee, Mi Joo Chung, Yun Hee Lee, Ji Hyun Chang & Yeon Sil Kim

  2. Department of Radiation Oncology, School of Medicine, Ewha Womans University, Seoul, South Korea

    Kyung Ran Park

  3. Division of Pulmonology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea

    Seung Joon Kim

  4. Department of Medical Oncology, College of Medicine, The Catholic University of Korea, Seoul, South Korea

    Jin Hyoung Kang & Sook Hee Hong

  5. Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea

    Myung Sin Kim

Authors
  1. Dong Soo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kyung Ran Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seung Joon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mi Joo Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yun Hee Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ji Hyun Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jin Hyoung Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sook Hee Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Myung Sin Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yeon Sil Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yeon Sil Kim.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, D.S., Park, K.R., Kim, S.J. et al. Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes. Tumor Biol. 37, 619–625 (2016). https://doi.org/10.1007/s13277-015-3776-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3776-5

Keywords

Search

Navigation